Related Experiment Videos
[Allergic bronchial asthma treated with Loratadine]
V M Kroll1, B Nothofer, K Werdermann
1Asthma-Krankenhaus, Kamillianer, Mönchengladbach.
Fortschritte Der Medizin
|February 20, 1993
Summary
Loratadine, an antihistamine, effectively improved symptoms and lung function in patients with persistent allergic bronchial asthma when used as an add-on treatment. This study highlights its potential for managing asthma symptoms.
Area of Science:
- Allergy and Immunology
- Pulmonology
- Pharmacology
Background:
- Allergic bronchial asthma is a chronic respiratory condition.
- Persistent asthma requires effective adjunctive treatments.
- Antihistamines are explored for their role in asthma management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of loratadine.
- To assess loratadine as an adjunctive therapy for persistent allergic bronchial asthma.
Main Methods:
- An 8-week open clinical trial involving 25 ambulatory patients.
- Patients continued existing asthma treatments.
- A 6-week treatment phase with 10 mg daily loratadine after a 2-week observation period.
Main Results:
- Significant improvement in lung function parameters (up to 21%) and symptom scores.
- Reduced apneic events (52%) and coughing attacks.
- Decreased use of inhaled sympathomimetics; 71% of patients reported good therapeutic response.
Conclusions:
- Loratadine demonstrates a positive effect on symptomatology in allergic bronchial asthma.
- It serves as a beneficial adjuvant therapeutic agent.
- The findings support loratadine's role in managing persistent asthma.